REG - T.Rowe Price Assoc - Form 8.3 - [AbbVie Inc]
RNS Number : 8263GT.Rowe Price Associates19 March 2020Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing (Note 1)
T. ROWE PRICE ASSOCIATES, INC.
Company dealt in
ABBVIE INC
Class of relevant security to which the dealings being disclosed relate (Note 2)
ISIN: US00287Y1091
Date of dealing
18 March 2020
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
44,289,755 2.99%
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
44,289,755 2.99%
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)
Class of relevant security:
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 5)
Purchases
Sales
1,600
1,797
21,700
2,500
145,390
16,620
35,500
11,023
628
754
3,053
4,967
300,000
200
4,200
66.130 USD
66.623 USD
67.146 USD
69.175 USD
71.030 USD
65.965 USD
66.082 USD
66.272 USD
66.483 USD
67.321 USD
67.906 USD
68.362 USD
68.806 USD
69.135 USD
71.030 USD
(b) Derivatives transactions (other than options transactions)
Product name,
e.g. CFD
Nature of transaction
(Note 6)
Number of relevant securities
(Note 7)
Price per unit
(Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,
e.g. call option
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise price
Type, e.g. American, European etc.
Expiry date
Option money paid/received per unit (Note 5)
(ii) Exercising
Product name,
e.g. call option
Number of securities
Exercise price per unit (Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction
(Note 8)
Details
Price per unit
(if applicable) (Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure
19 March 2020
Contact name
Gary Greb
Telephone number
001 410 345 2527
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDISEKKCBNBBKDCND
Recent news on T Rowe Price
See all newsREG - T.Rowe Price Assoc Horizon Therapeutics - Form 8.3 - Horizon Therapeutics Plc
AnnouncementREG - T.Rowe Price Assoc Horizon Therapeutics - Form 8.3 - Horizon Therapeutics Plc
AnnouncementREG - T.Rowe Price Assoc Horizon Therapeutics - Form 8.3 - Horizon Therapeutics Plc
AnnouncementREG - T.Rowe Price Assoc - Form 8.3 - Horizon Therapeutics Plc
AnnouncementREG - T.Rowe Price Assoc Horizon Therapeutics - Form 8.3 - Horizon Therapeutics Plc
Announcement